The biopharmaceutical industry is currently facing a number of macro-environmental factors, which underscore its need to think of itself not as a developer of singular products, but as a critical part of an interoperable system. This fundamental shift must include a strategic approach for engaging with an increasingly informed and connected patient population. The amount of medical information now available to patients online is truly remarkable. Coupled with a decrease in the amount of time physicians can actually spend with their patients, today’s health care consumers are savvy, engaged and have a strong desire to learn as much as they can about their diseases.

By not directly engaging with patients, biopharmaceutical companies are missing an enormous opportunity to reduce the time and cost of clinical development and maximize the return on their development investments. However, by earning patient trust and creating a two-way dialog, some companies have been able to engage patients to participate and remain in research; prove product value and safety by directly gathering personal outcomes, medical records, and diagnostic data from labs or devices; and accelerate product adoption and adherence.

This white paper discusses how biopharmaceutical companies can harness the power of the digital patient when it engages them in the appropriate manner. Quintiles’ Digital Patient Unit was founded to continue to innovate around these areas of opportunity.